Together, the companies aim to receive 4D-150 marketing approval and commercialization in ... are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food ...
There are three obstacles to faster development and deployment of non-addictive pain treatments. They are the business ...
A month’s supply of Miebo requires $800 and a prescription in the U.S. In Europe, it’s over-the-counter and $20.
DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years ...
BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience innovator specializing in ...
The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative “biosimilar” versions of biologic drugs as a way to curb health costs. The ...
Laxxon Medical, a leading pharmaceutical technology company, pioneering a new generation of advanced oral drug delivery systems, today announced that it will be attending BIO-Europe 2025 and the ...
From the discovery of novel drug candidates to the delivery of advanced genetic therapies, enterprises are beginning to show how artificial intelligence can generate breakthroughs that may reshape the ...
Revolutionary progress, like that of GLP-1 drugs, happens when many exceptional people work together, following a robust ...
Hosted on MSN
Between hype and hope: Seattle biotech leaders size up AI’s real impact on drug development
Dozens of Seattle biotech companies are using artificial intelligence to design new medical treatments. But at a conference of industry leaders and investors this week, scientists delivered a nuanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback